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Posterior fossa malformations, large infantile hemangioma of the head neck or 
face, arterial cerebrovascular anomalies, cardiac anomalies, and eye anomalies define the 
acronym for PHACE syndrome. PHACE syndrome (OMIM no. 606519) is a 
neurocutaneous syndrome with unknown etiology and pathogenesis. We report on an 
individual with PHACE syndrome with a complete deletion of SLC35B4 in the 7q33 
region. In order to further analyze this region, SLC35B4 was sequenced for 33 individuals 
with PHACE syndrome and one parental set.  Common polymorphisms with a possible 
haplotype but no disease causing mutation were identified. Sixteen of 33 samples of the 
PHACE syndrome patients were also analyzed for copy number variations using high 
resolution oligo-Comparative Genomic Hybridization (CGH) microarray. A second 
individual in this cohort had a 26.5kb deletion approximately 80kb upstream of SLC35B4 
with partial deletion of the AKR1B1 gene in the 7q33 region. The deletions observed on 
7q33 are not likely the singular cause of PHACE syndrome; however, it is possible that 
this region provides a genetic susceptibility to phenotypic expression with other 
confounding genetic or environmental factors. 
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 This manuscript is reprinted with permission from John Wiley & Sons, Inc.  Sheri 
Mitchell, Dawn H. Siegel, Joseph T. Shieh, et. al.  Candidate locus analysis for PHACE 
syndrome.  American Journal of Medical Genetics Part A. Copyright © (2012) Wiley 
Periodicals, Inc. 
Seven females with cervicofacial hemangiomas along with other anomalies were 
described by Pascual-Castroviejo in 1978 [Pascual-Castroviejo,1978]. This association 
was further defined, and the acronym PHACE was proposed in 1996 by Frieden et al. 
[Frieden et al.,1996]. PHACE syndrome includes posterior fossa malformations, large 
infantile hemangioma of the head neck or face, arterial cerebrovascular anomalies, 
cardiac anomalies, and eye anomalies.  Sternal clefting and/or supraumbilical raphe can 
also be present, and is referred to as PHACES syndrome (OMIM # 606519) [Frieden et 
al.,1996] . 
Large facial hemangiomas indicative of PHACE syndrome are often described as 
segmental; they comprise approximately 20% of hemangiomas identified in the head and 
neck region [Haggstrom et al.,2006]. In most cases, a diagnosis of PHACE syndrome 
includes a segmental hemangioma of > 5cm in diameter of the head, neck, or face and 
one extracutaneous anomaly. In 2009, leading experts established both major and minor 
criteria based on the particular organ system to better define PHACE syndrome [Metry et 




cerebral arteries (dysplasia, arterial stenosis, and persistence of trigeminal artery), 
structural brain anomalies (Dandy-Walker complex, posterior fossa anomaly), 
cardiovascular anomalies (coarctation of the aorta, or aneurysm), ocular anomalies 
(posterior segment abnormality, retinal vascular or morning glory disc anomaly), and  
ventral or midline anomalies (sternal defects).   Minor criteria include the persistence of 
embryonic arteries, midline anomalies, ventricular septal defects, cataracts, or 
hypopituitarism.  A definition of PHACE syndrome based on these criteria would include 
a segmental hemangioma >5cm in diameter of the head, neck, or face plus either one of 
the major criteria or 2 minor criteria.  
To date there have been more than 300 cases of PHACE syndrome reported in the 
literature [Haggstrom et al.,2010] but the etiology and pathogenesis of PHACE syndrome 
still remains unknown. To investigate a possible genetic origin for the pathogenesis of 
PHACE syndrome, genomic oligo-Comparative Genomic Hybridization (CGH) 
microarray was used to evaluate a patient with PHACE syndrome identifying a small 
novel deletion on 7q33.  This region was subsequently analyzed in a larger cohort of 
PHACE syndrome cases and the results are reported here. 
A small deletion of approximately 100kb in size located on chromosome 7q32 
was identified in a patient that was diagnosed with PHACE.  The affected gene in this 
region was SLC35B4. It is a glycosyltransferase that transports sugar from the cytoplasm 
to the Golgi apparatus [Ashikov et al.,2005]. This gene has not been defined in the 
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DNA was obtained from 5 subjects with PHACE syndrome through the Utah 
Clinical Genetics Research Program, Istanbul Medical Faculty, Istanbul University, and 
DNA from 28 additional individuals with PHACE syndrome and 2 unaffected parents 
was obtained from the PHACE Syndrome International Clinical Registry and Genetic 
Repository. All affected subjects met diagnostic criteria for PHACE syndrome based on 
the diagnostic criteria of Metry et al. [Metry et al.,2009a].  Diagnostic criteria include a 
large hemangioma on the face measuring 5 cm or more plus at least one major criteria 
such as a posterior fossa anomaly, coarctation of the aorta, developmental anomalies of 
the great cerebral arteries, developmental posterior segment eye anomalies and midline 
ventral defects, such as sternal cleft. Information was obtained from physical 
examinations and medical histories (e.g., results from echocardiograms, brain and vessel 
imaging, and ophthalmologic examinations.  





via Cesarean section due to abruptio placentae.  A faint red birthmark involving the right 
side of the face in a segmental pattern was noted at birth.  The infant was admitted to the 
neonatal intensive care unit for care. Magnetic resonance imaging (MRI) of the brain at 1 
week of age showed a dysplastic right superior vermis, an absent inferior vermis, a 
hypoplastic right dural venous sinus, and an abnormal enhancement of the anterior 
chamber of the right eye. Repeat MRI imaging at 1 month of age showed an increase in 
the size and number of proliferating hemangiomas within the right frontal scalp, right 
orbit and soft tissues of the face.  Additional intracranial foci were identified in the right 
petrous apex, subarachnoid space, and pituitary gland.  The circle of Willis was noted to 
be aberrant and there was a slight increase in the amount of flow-voids in the 
supracerebellar cistern.  Computed tomography (CT) of the chest and abdomen showed 
multiple contrast-enhancing lesions within the chest wall, right hepatic lobe, and bowel 
wall.  Ophthalmologic exam showed sclerocornea, a persistent papillary membrane, and a 
small superior optic nerve.  An echocardiogram was normal.  There was no obvious 
sternal cleft. The infant developed necrotizing enterocolitis with bowel perforation 
requiring bowel resection. At surgery multiple hemangiomas were visible throughout the 
small intestines. A second surgery was required in which the entire small intestine was 
determined to be nonviable.  Support was withdrawn at approximately 2 months of age  
in a series by Drolet et al. 2011 [Drolet BA,2011 (submitted)]. 
 
DNA Isolation 







A minimum of 500ng and up to 1µg of purified DNA was used on the microarray 
depending on the amount of sample available.  Reference DNA that consisted of a pool 
from 10 healthy individuals was used as sex matched control (Promega GmbH, 
Mannheim, Germany) when the sex of the patient was known.   
Further data analysis was performed for all of the samples using the Nexus Copy 
Number software (BioDiscovery, Inc., El Segundo, CA) to analyze compatible samples at 
one time. Deletions or duplications that were detected with 10 data points or more and 
had a log2 ratio greater than +0.3 were considered significant.  Quality scores of 0.200 or 
less were considered to be excellent. Scores between 0.200 and 0.300 were further 
evaluated by taking the total number of gains/losses (base pairs) and dividing it by the 
total amount of genomic material. Samples that had 0.5% or less variability were 
considered valid. The regions of deletions or duplications were compared between 
samples.   
A total of 24 samples (22 proband, 2 unaffected parents) out of 35 had a sufficient 
amount of DNA to perform the human CGH  3 x 720K whole genome tiling array (Roche 
Nimblegen, Inc., Madison, WI) DNA labeling (Nimblegen Dual-Color DNA Labeling 
Kit , Roche Nimblegen, Inc., Madison, WI), hybridization (Nimblegen Hybridization Kit, 
Roche Nimblegen, Inc., Madison, WI), and washing were performed according to the 
package insert.  Data analysis was performed using Nimblescan (Roche Nimblegen, Inc., 
Madison, WI) and results were viewed using SignalMap (Roche Nimblegen, Inc., 
Madison, WI).  Further data analysis was performed for all of the samples using the 




duplications that were detected with 10 data points or more and had a log2 ratio greater 
than +0.3 were considered significant.  Quality scores that were calculated using the 
Nexus software were used to determine if the sample data were valid. Quality scores of 
0.200 or less were considered to be excellent. Scores between 0.200 and 0.300 were 
further evaluated by taking the total number of gains/losses (base pairs) and dividing it by 
the total amount of genomic material. Samples that had 0.5% or less variability were 
considered valid. Any sample with a quality score that was greater than 0.3 was excluded. 
In addition, sample data exhibiting greater than 1% variability in the genome were 
excluded.  The regions of deletions or duplications were compared between samples.  For 
purposes of this report, the 7q33 region was specifically analyzed. Results from an 
additional archived 24 normal control samples were further analyzed for the 7q33 region 
exclusively. These archived normal control samples were processed using various CGH 





Whole genome amplification was performed on all of the samples for Sanger 
sequencing using the Illustra GenomiPhi  DNA Amplification Kit (GE Healthcare Bio-
Sciences Corp Piscataway, NJ). For cases in which there was not sufficient amount of 
DNA to perform the microarray (<500ng), only Sanger sequencing was performed on the 
selected candidate gene (SLC35B4). 
Sanger sequencing using big dye terminator was performed on the SLC35B4 gene 
10 coding exons for 35 samples including 33 probands, and 1 unaffected parental set.  




PCR was performed using approximately 50-75ng of genomic DNA.  Forward and 
reverse primers were added at 10µM each with 12.5µL of High Fidelity PCR Master mix 
(Roche, Mannheim, Germany). Bidirectional sequencing was performed on a 3730 ABI 
DNA Genetic Analyzer, using forward and reverse primers.  Analysis was performed 
using Mutation Surveyor (SoftGenetics, LLC., State College, PA) for any difference from 
the reference sequence that would result in a non-synonymous mutation.  Single 
nucleotide polymorphisms that were identified were evaluated using Alamut (Interactive 








All probands met diagnostic criteria for PHACE syndrome [Metry et al.,2009a].  
Using the Nimblegen 3 x 720K whole genome tiling array, a novel small deletion (-0.7 
log2 ratio) of approximately 100kb in size located on chromosome 7q33 (chr7: 
133,600,015- 133,700,204, NCBI36/hg18) was identified in participant 1 (see Figure 1A) 
(clinical description above).  This is a small region containing one gene, SLC35B4 (chr7: 
133,624,630-133,652,343, NCBI36/hg18), that was deleted.  Parental samples were not 
available in order to determine de novo or familial status of the deletion. This region is 
highly conserved (see Figure 1B). 
Out of the 33 probands, in which sequencing was performed for one candidate 
gene (SLC35B4) based on the CGH microarray results, 11 probands showed no variation.  
In the other 22 probands 7 SNPs were identified in the introns and 1 synonymous SNP 
detected in the exon of SLC35B4 (rs447266, rs34664116, rs2075372, rs1832052, 
rs1421484, rs2241336, rs2505, rs2504).  All of these SNPs were previously identified 
and common within the population.  In all but two cases, these SNPs (7 intronic, 1 
exonic) were found together in each sample, indicating a possible haplotype. As 
expected, participant #1 with the SLC35B4 deletion in this region did not have any SNPs 
in the heterozygous position. Subsequently, 24 samples (22-proband, 1 parental set- 
father and mother of participant #15) were run on the Nimblegen 3 x 720K whole 






Figure 1A. Summary of affected probands plus the unaffected parental set. Figure 1B. 
Conservation of 28 mammalian species including 17 placental mammal species and 
human for the 7q33 region. 
 
 
samples. Out of 2 samples run on the array, 6 samples were eliminated because either the 
quality scores were above 0.3 or due to aberrant microarray results.  A total of 16 samples 
from the probands and unaffected parental set were CNVconsidered valid for analysis. 
CGH array data from 24 randomly selected healthy control samples were analyzed 
exclusively for SLC35B4. There were no deletions or duplications identified in this 
region for the healthy controls.   
Interestingly, participant #15, had a 26.5kb deletion approximately 80kb upstream 
(chr7: 133,783,161- 133,809,611, NCBI36/hg18) of SLC35B4 (clinical description in 
clinical report section).  In this patient 16.3kb out of 16.8kb of the AKR1B1 gene (aldo-
keto reductase family 1, member B1) is deleted (chr7:133,777,647-133,794,428, 
NCBI36/hg18). Participant #15 is a Caucasian female born full term to a primiparous 27 
year-old woman. The birth weight was 4kg. There were no reported pregnancy 




with extension onto the neck and upper chest. A subglottic hemangioma was also present. 
The brain imaging was normal. An echocardiogram revealed an interrupted aortic arch 
and a ventricular septal defect. There were no eye anomalies or sternal defects. 
Additional complications included scoliosis and unilateral hearing loss. The identical 
deletion was also identified in the mother. The mother did not have vascular anomalies, 
hemangiomas or other reported medical conditions. She had a normal echocardiogram, 
but an angiogram has not been performed. When the mother’s CNV regions were 
compared with those of participant #15, nine novel deletion/duplication regions were 
identified in the child’s sample. The percent variability in the genome was much higher 
for the child compared to the mother (0.13% versus 0.06%, respectively). The other 14 
individuals with PHACE syndrome had no significant changes in the 7q33 region on the 
CGH microarray. There were no other non-CNV regions in the whole genome that 
contained genes where deletions or duplications showed an overlap in at least 2 samples. 
When one looked at CNV regions present in at least 25% of the samples from individuals 
with PHACE syndrome, seven CNV regions were identified. All of these CNV regions 
identified have been previously recognized as common CNVs in the normal population. 
Variability within the genome using our cut-off criteria for all samples ranged from 







Out of 16 individuals with PHACE syndrome in which CGH microarray results 
could be analyzed, 2 had small deletions on chromosome 7q33 region. This region 
contains SLC35B4 and AKR1B1.  SLC35B4 (solute carrier family 35, member B4) is a 
glycosyltransferase that transports sugar from the cytoplasm to the Golgi apparatus 
[Ashikov et al.,2005]. No disease causing mutations are reported in the literature related 
with SLC35B4 and AKR1B1. However, repeat dinucleotide and single nucleotide 
polymorphisms in the AKR1B1 gene have been reported in association with diabetic 
macroangiopathy, diabetic retinopathy, and diabetic nephropathy, and cardiorenal 
complications [So et al.,2008; Thamotharampillai et al.,2006; Wolford et al.,2006; Xu et 
al.,2008]. None of them had deletions of AKR1B1. In addition, we showed that 24 healthy 
controls did not have any structural changes in this region and no CNVs have been 
reported in this deleted region. The deletions found in our 2 patients are novel changes 
not previously linked with any disease. The deletions in these 2 patients do not overlap; 
however, the breakpoints are 80 kb apart and located on the 5’ upstream regions of 
SLC35B4. Regulatory proteins or transcription factors related to the regulation of 
SLC35B4 binding sites may have been affected by these deletions in both patients. 
Expression studies have shown that SLC35B4 is expressed in the fetal brain and heart 





al.,2002; Su et al.,2004; Wu et al.,2009] (http://genome.ucsc.edu/, genome hg18.)  We 
further investigated SLC35B4 and sequenced the exons and exon-intron boundaries for all 
individuals with PHACE syndrome in our cohort, but there were no mutations identified, 
suggesting that exonic sequence changes in SLC35B4 were not associated in our cohort 
of individuals with PHACE syndrome.  It is unclear if the haplotype identified for some 
of the samples could be associated with PHACE syndrome.  
The mother of participant #15 has the identical deletion in AKR1B1 and as far as 
we know is clinically unaffected. When the mother’s CNV regions were compared with 
child’s we identified nine novel deletion/duplication regions in the child’s sample. The 
differences in genetic background, including CNVs inherited by both parents and de novo 
deletions/duplications, could contribute to the presentation of PHACE syndrome via 
epistatic effects [Eichler et al.,2010]. However, in this case, we feel it is unlikely that this 
small, inherited deletion in AKR1B1 is the causative genetic alteration in this patient. 
Although a single genetic etiology for PHACE syndrome has not been identified, it could 
be multifactorial and heterogeneous, contributing to the variable clinical presentation. 
Environmental factors or physical conditions such as pre-eclampsia and premature births 
may contribute to expression of the phenotype. The clinical variability of PHACE 
syndrome makes a diagnosis at times tenuous, but important for proper clinical care.  So 
far, PHACE syndrome consists primarily of simplex cases without an obvious inheritance 
pattern.  Although, the deletions observed on 7q33 are not likely the singular cause of 
PHACE syndrome it is possible that this region provides a genetic susceptibility to 
phenotypic expression in combination with other inherited or de novo CNVs  [Girirajan 




The presence of segmental hemangiomas is typical for PHACE syndrome.  The 
segmental/unilateral findings in PHACE syndrome provide some support for a two-hit or 
multistep model.  We hypothesize that PHACE syndrome is multifactorial and that there 
are genetic predisposing factors that in combination with other possible genetic and 
environmental influences result in the wide phenotypic spectrum of findings seen in 
PHACE syndrome. Molecular studies on DNA from different tissue types such as the 
hemangioma tissue looking for somatic events including deletions of the 7q33 region 
would be interesting.  In addition, future studies in larger cohorts investigating germline 
changes of the 7q33 region will be helpful. It may also be valuable to catalogue the 
common CNVs between individuals as these may contribute to the variable phenotype 
observed for PHACE syndrome.  Our current cohort provides high resolution copy 
number change information with 720,000 probes throughout the whole genome in 16 
individuals with PHACE syndrome.  Although based on only 2 individuals, the 7q33 
region is a potential candidate locus for further studies to be undertaken in revealing the 
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